MedPath

A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)

Recruiting
Conditions
Pyoderma Gangrenosum
Registration Number
NCT04750213
Lead Sponsor
AbbVie
Brief Summary

Pyoderma Gangrenosum (PG) is a rapidly progressive disease and presents as painful, single or multiple lesions, with several clinical variants, in different locations, with a nonspecific histology, which makes the diagnosis challenging and often delayed. The main objective of this study is to estimate the incidence proportion of all the infection reported as adverse drug reaction (ADR) of Humira with PG participants.

Humira is the only drug approved for the treatment of Pyoderma Gangrenosum (PG) in Japan. Approximately 60 adult participants with PG at approximately 60 sites in Japan.

Participants will receive injectable Humira (Adalimumab) as prescribed by the physician prior to enrolling in this study.

There may be a higher burden for participants in this study compared to standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and by verbal interview.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Diagnosed with Pyoderma Gangrenosum (PG).
  • Have been prescribed Humira for PG treatment within 14 days.
Exclusion Criteria
  • Have Pyoderma Gangrenosum (PG) in previous treatment with Humira.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence Percentage of all the Infection Reported as Adverse Drug Reaction (ADR)Up to 52 weeks

An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. Among AEs, an event whose causal relationship with the product cannot be ruled out is considered an adverse drug reaction.

Secondary Outcome Measures
NameTimeMethod
Change in Verbal Rating Scale (VRS) CategoryUp to Week 52

Pain improvement will be assessed using a VRS scale 0-3 with a lower score indicating less pain.

Incidence Percentage of Serious Infection Reported as ADRUp to 52 weeks

An AE is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. Among AEs, an event whose causal relationship with the product cannot be ruled out is considered an adverse drug reaction.

Change in Investigator Inflammation Assessment (IIA) Score from Start of DosingUp to Week 52

IIA will be used for assessment of efficacy of target lesions.

Time to Recurrence (Day)Up to Week 52

Recurrence of PG.

Pain Improvement Assessed with VRSWeek 26 to Week 52

Pain improvement will be assessed using a VRS scale 0-3 with a lower score indicating less pain.

Incidence Percentage of each ADR (Besides Infection)Up to 52 weeks

An AE is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. Among AEs, an event whose causal relationship with the product cannot be ruled out is considered an adverse drug reaction.

Percentage of Participants with RecurrenceUp to Week 52

Recurrence of PG.

Change in PGA [Target] GradeUp to Week 52

PGA will be used for assessment of efficacy of target lesions.

Percentage of PG Subtype at RecurrenceUp to Week 52

Recurrence of PG. PG subtypes include (ulcerative (including peristomal), bullous, pustular, vegetative).

Change in Physician's Global Assessment (PGA) [Global] GradeUp to Week 52

PGA will be used for overall assessment of efficacy.

Trial Locations

Locations (46)

Kumamoto University Hospital /ID# 244050

๐Ÿ‡ฏ๐Ÿ‡ต

Kumamoto shi, Kumamoto, Japan

Okinawa Kyodo Hospital /ID# 241739

๐Ÿ‡ฏ๐Ÿ‡ต

้‚ฃ่ฆ‡ๅธ‚, Okinawa, Japan

Japanese Red Cross Osaka Hospital /ID# 228782

๐Ÿ‡ฏ๐Ÿ‡ต

Osaka-shi, Osaka, Japan

Fukuchiyama City Hospital /ID# 246593

๐Ÿ‡ฏ๐Ÿ‡ต

Fukuchiyama-shi, Japan

Okayama University Hospital /ID# 238746

๐Ÿ‡ฏ๐Ÿ‡ต

Okayama, Japan

Hokkaido Medical Center /ID# 251657

๐Ÿ‡ฏ๐Ÿ‡ต

Sapporo-shi, Japan

Kurume University Hospital /ID# 246502

๐Ÿ‡ฏ๐Ÿ‡ต

Kurume-shi, Fukuoka, Japan

Kyushu University Hospital /ID# 247492

๐Ÿ‡ฏ๐Ÿ‡ต

Fukuoka-shi, Fukuoka, Japan

Sapporo Medical University Hospital /ID# 241180

๐Ÿ‡ฏ๐Ÿ‡ต

Sapporo-shi, Hokkaido, Japan

Kansai Rosai Hospital /ID# 246592

๐Ÿ‡ฏ๐Ÿ‡ต

Amagasaki-shi, Hyogo, Japan

Nagoya City University Hospital /ID# 233778

๐Ÿ‡ฏ๐Ÿ‡ต

Nagoya shi, Aichi, Japan

NHO Nagoya Medical Center /ID# 246013

๐Ÿ‡ฏ๐Ÿ‡ต

Nagoya-shi, Aichi, Japan

Hokkaido University Hospital /ID# 252567

๐Ÿ‡ฏ๐Ÿ‡ต

Sapporo-shi, Hokkaido, Japan

Akita University Hospital /ID# 242706

๐Ÿ‡ฏ๐Ÿ‡ต

Akita-shi, Akita, Japan

Nara Medical University Hospital /ID# 241880

๐Ÿ‡ฏ๐Ÿ‡ต

Kashihara-shi, Nara, Japan

Hamamatsu University Hospital /ID# 240817

๐Ÿ‡ฏ๐Ÿ‡ต

Hamamatsu-shi, Shizuoka, Japan

Teikyo University /ID# 239389

๐Ÿ‡ฏ๐Ÿ‡ต

Tokyo, Japan

Yamanashi Kosei Hospital /ID# 242168

๐Ÿ‡ฏ๐Ÿ‡ต

Yamanashi City, Yamanashi, Japan

Ishikawa Prefectural Central Hospital /ID# 239089

๐Ÿ‡ฏ๐Ÿ‡ต

Kanazawa-shi, Ishikawa, Japan

Naha City Hospital /ID# 240818

๐Ÿ‡ฏ๐Ÿ‡ต

Naha, Okinawa, Japan

Kansai Medical University Hospital /ID# 228783

๐Ÿ‡ฏ๐Ÿ‡ต

Hirakata-shi, Osaka, Japan

Tokyo Medical University Hospital /ID# 233780

๐Ÿ‡ฏ๐Ÿ‡ต

Shinjuku-ku, Tokyo, Japan

Kanazawa University Hospital /ID# 248730

๐Ÿ‡ฏ๐Ÿ‡ต

Kanazawa-shi, Ishikawa, Japan

Kagawa Prefectural Central Hospital /ID# 250193

๐Ÿ‡ฏ๐Ÿ‡ต

Takamatsu-shi, Kagawa, Japan

Yokohama Municipal Citizen's Hospital /ID# 233779

๐Ÿ‡ฏ๐Ÿ‡ต

Yokohama-shi, Kanagawa, Japan

Kindai University Hospital /ID# 252568

๐Ÿ‡ฏ๐Ÿ‡ต

Osakasayama-shi, Osaka, Japan

Takatsuki General Hospital /ID# 244694

๐Ÿ‡ฏ๐Ÿ‡ต

Osaka, Japan

The Jikei University Hospital /ID# 252112

๐Ÿ‡ฏ๐Ÿ‡ต

Minato-ku, Tokyo, Japan

Teikyo University Mizonokuchi Hospital /ID# 244693

๐Ÿ‡ฏ๐Ÿ‡ต

Kawasaki, Kanagawa, Japan

University of Miyazaki Hospital /ID# 241179

๐Ÿ‡ฏ๐Ÿ‡ต

Miyazaki-shi, Miyazaki, Japan

Japanese Red Cross Fukuoka Hospital /ID# 244051

๐Ÿ‡ฏ๐Ÿ‡ต

Fukuoka-shi, Fukuoka, Japan

Central Japan International Medical Center /ID# 239391

๐Ÿ‡ฏ๐Ÿ‡ต

Minokamo-shi, Gifu, Japan

Gunma University Hospital /ID# 239390

๐Ÿ‡ฏ๐Ÿ‡ต

Maebashi-shi, Gunma, Japan

Nishi-Kobe Medical Center /ID# 244224

๐Ÿ‡ฏ๐Ÿ‡ต

Kobe-shi, Hyogo, Japan

Kobe University Hospital /ID# 249396

๐Ÿ‡ฏ๐Ÿ‡ต

Kobe, Hyogo, Japan

Takamatsu Red Cross Hospital /ID# 240576

๐Ÿ‡ฏ๐Ÿ‡ต

Takamatsu-shi, Kagawa, Japan

Yokohama Minami Kyousai Hosp /ID# 252892

๐Ÿ‡ฏ๐Ÿ‡ต

Yokohama-shi, Kanagawa, Japan

Mie University Hospital /ID# 238747

๐Ÿ‡ฏ๐Ÿ‡ต

Tsu-shi, Mie, Japan

Tohoku Medical and Pharmaceuti /ID# 230270

๐Ÿ‡ฏ๐Ÿ‡ต

Sendai-shi, Miyagi, Japan

Tohoku University Hospital /ID# 252113

๐Ÿ‡ฏ๐Ÿ‡ต

Sendai-shi, Miyagi, Japan

Shinshu University Hospital /ID# 230272

๐Ÿ‡ฏ๐Ÿ‡ต

Matsumoto-shi, Nagano, Japan

University of the Ryukyus Hospital /ID# 252114

๐Ÿ‡ฏ๐Ÿ‡ต

Nakagami-gun, Okinawa, Japan

Dokkyo Medical University Saitama Medical Center /ID# 248731

๐Ÿ‡ฏ๐Ÿ‡ต

Koshigaya, Saitama, Japan

The University of Tokyo Hospital /ID# 250194

๐Ÿ‡ฏ๐Ÿ‡ต

Bunkyo-ku, Tokyo, Japan

Chutoen General Medical Center /Id# 228780

๐Ÿ‡ฏ๐Ÿ‡ต

Kakegawa-shi, Shizuoka, Japan

Shizuoka Saiseikai Genaral Hospital /ID# 239088

๐Ÿ‡ฏ๐Ÿ‡ต

Shizuoka-shi, Shizuoka, Japan

ยฉ Copyright 2025. All Rights Reserved by MedPath